Purpose: This study aimed to compare the wet bulb globe temperature (WBGT) index and other environmental parameters between early and late Boston Marathon race start times from 1995 to 2016.
Methods: Environmental data from 1995 to 2016 (excluding 1996) were used to compare two identical time frames using the 0900-1300 h start versus the 1100-1500 h start. This included the WBGT, dry bulb (Tdb), black globe (Tbg), wet bulb (Twb), solar radiation, relative humidity, and air water vapor pressure. To make comparisons between start times, the difference in the area under the curve (AUC) for each environmental variable was compared within each year with a Wilcoxon signed rank test with a Holm-Bonferroni correction.
Results: AUC exposures for WBGT (P = 0.027), Twb (P = 0.031), Tdb (P = 0.027), Tbg (P = 0.055), and solar radiation (P = 0.004) were reduced with an earlier start, whereas those for relative humidity and air water vapor pressure were not. Overall, an earlier race start time by 2 h (0900 vs 1100 h) reduced the odds of experiencing a higher flag category 1.42 times (β = 0.1744, P = 0.032).
Conclusions: The 2007 decision to make the Boston Marathon start time earlier by 2 h has reduced by ~1.4 times the odds that runners will be exposed to environmental conditions associated with exertional heat illness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1249/MSS.0000000000002659 | DOI Listing |
Lancet HIV
January 2025
Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Background: Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) risk scores used in clinical guidelines perform among people with HIV globally.
Methods: In this prospective cohort study leveraging REPRIEVE data, we included participants aged 40-75 years, with low-to-moderate traditional cardiovascular risk, not taking statin therapy.
Introduction: Age-associated depletion in nicotinamide adenine dinucleotide (NAD+) concentrations has been implicated in metabolic, cardiovascular, and neurodegenerative disorders. Supplementation with NAD+ precursors, such as nicotinamide riboside (NR), offers a potential therapeutic avenue against neurodegenerative pathologies in aging, Alzheimer's disease, and related dementias. A crossover, double-blind, randomized placebo (PBO) controlled trial was conducted to test the safety and efficacy of 8 weeks' active treatment with NR (1 g/day) on cognition and plasma AD biomarkers in older adults with subjective cognitive decline and mild cognitive impairment.
View Article and Find Full Text PDFJ Prev Alzheimers Dis
January 2025
Alzheimer's Drug Discovery Foundation, New York, NY, USA. Electronic address:
There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions and decisions for study sponsors, from preclinical research through clinical trial design to regulatory, statistical, and operational considerations. In January 2024, the Alzheimer's Drug Discovery Foundation convened an expert advisory board to discuss the key considerations in each of these areas.
View Article and Find Full Text PDFAlzheimers Dement (N Y)
November 2024
Department of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
Objective: Physical activity (PA) has been linked to reduced Alzheimer's disease (AD) risk. However, less is known about its effects in the AD preclinical stage. We aimed to investigate whether greater PA was associated with lower plasma biomarkers of AD pathology, neural injury, reactive astrocytes, and better cognition in individuals with autosomal-dominant AD due to the presenilin-1 E280A mutation who are virtually guaranteed to develop dementia.
View Article and Find Full Text PDFGait Posture
December 2024
Division of Sports Medicine, Department of Orthopedics, Boston Children's Hospital, Boston, MA, United States; Harvard Medical School, Harvard, MA, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!